Search Result

Results for "

STING agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	STING (118) ADC Payload (3) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (2) Autophagy (4) Bacterial (3) Calcium Channel (3) Cathepsin (1) CD28 (1) CXCR (2) Cyclic GMP-AMP Synthase (2) Drug Derivative (1) Drug-Linker Conjugates for ADC (7) EGFR (1) Endogenous Metabolite (8) IFNAR (12) IKK (2) Influenza Virus (2) Interleukin Related (7) Isotope-Labeled Compounds (1) NF-κB (1) PPAR (1) PROTACs (1) Ras (3) Reactive Oxygen Species (ROS) (2) Reference Standards (3) SARS-CoV (1) TNF Receptor (4) Virus Protease (1)
By Research Areas:	Cancer (93) Cardiovascular Disease (3) Infection (19) Inflammation/Immunology (40) Neurological Disease (1)
Click Chemistry:	DBCO (1) Alkynes (1)
Oligonucleotides:	CpG ODNs (1)

122

Inhibitors & Agonists

Fluorescent Dye

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: STING

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112921A

*diABZI STING* agonist-1** 45+ Cited Publications	STING	Inflammation/Immunology
diABZI STING agonist-1 is a tautomerism of diABZI STING agonist-1 tautomerism (HY-112921). diABZI STING agonist-1 is a selective stimulator of interferon genes *(STING)* receptor agonist, with EC₅₀s of 130, 186 nM for human and mouse, respectively .

HY-10964

Vadimezan Maximum Cited Publications 71 Publications Verification DMXAA; ASA-404	STING IFNAR Influenza Virus	Infection Cancer
Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.

HY-112921B

*diABZI STING* agonist-1 trihydrochloride** 45+ Cited Publications	STING	Inflammation/Immunology Cancer
diABZI STING agonist-1 (trihydrochloride) is a selective stimulator of interferon genes *(STING)* receptor agonist, with EC₅₀s of 130, 186 nM for human and mouse, respectively.

HY-136927

MSA-2 25+ Cited Publications	STING	Inflammation/Immunology Cancer
MSA-2, a potent and orally available non-nucleotide *STING* agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC₅₀s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models .

HY-103665

STING agonist-3 5+ Cited Publications	STING	Cancer
STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING* agonist* with a pEC₅₀ and pIC₅₀ of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer .

HY-148068

STING agonist-20	STING	Inflammation/Immunology Cancer
STING agonist-20 (compound 95) is a potent *STING* agonist used in the synthesis of XMT-2056. STING agonist-20 can be used as a vaccine adjuvant in the study of cancer and other inflammatory, immune diseases .

HY-123943

STING agonist-4 5+ Cited Publications	STING	Cancer
STING agonist-4 is an stimulator of Interferon Genes (STING) receptor agonist with an apparent inhibitory constant (IC₅₀) of 20 nM. STING agonist-4 is a two symmetry-related amidobenzimidazole (ABZI)-based compound to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function .

HY-112921

*diABZI STING* agonist-1 (tautomerism)** 2 Publications Verification	STING	Inflammation/Immunology
diABZI STING agonist-1 tautomerism is a tautomerism of diABZI STING agonist-1 (HY-112921A). diABZI STING agonist-1 tautomerism is a selective stimulator of interferon genes *(STING)* receptor agonist, with EC₅₀s of 130, 186 nM for human and mouse, respectively .

HY-19711

STING agonist-1 4 Publications Verification G10	STING Virus Protease	Infection
STING agonist-1 (G10) is human-specific *STING* agonist that elicits antiviral activity against emerging Alphaviruses. G10 potently blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) with IC₉₀ of 24.57 μM .

HY-143320

STING agonist-17	STING	Cancer
STING agonist-17 (compound 4a) is a potent *STING* agonist with an IC₅₀ value of 0.062 nM. STING agonist-17 has anti-cancer activity for tumor immunization .

HY-147010

STING agonist-12 2 Publications Verification	STING	Inflammation/Immunology
STING agonist-12 (Compound 53) is a potent, orally active human *STING* activator with an EC₅₀ of 185 nM .

HY-111999A

E7766 diammonium salt 4 Publications Verification	STING	Cancer
E7766 diammonium salt is a macrocycle-bridged *STING* agonist with a K_d of 40 nM. E7766 diammonium salt shows potent pan-genotypic and antitumor activities .

HY-148029

Dazostinag disodium TAK-676	STING	Cancer
Dazostinag disodium (TAK-676) is an agonist of *STING, triggering the activation of STING* signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity .

HY-162874

diABZI-V/C-DBCO	STING IFNAR	Cancer
diABZI-V/C-DBCO is a *STING* agonist with an EC₅₀ of 1.47 nM. diABZI-V/C-DBCO activates the *STING* pathway, induces the production of IFN-I, and stimulates the secretion of IFN-β. diABZI-V/C-DBCO serves as a substrate for cathepsin B, and releases active diABZI-amine via cathepsin B-mediated cleavage. In an orthotopic mouse model of breast cancer, diABZI-V/C-DBCO increases serum IFN-β levels and the frequency of granzyme B ⁺ CD8 ⁺ T cells. diABZI-V/C-DBCO is applicable to research related to triple-negative breast cancer .

HY-152955

STING agonist-22 1 Publications Verification	STING	Infection Inflammation/Immunology
STING agonist-22 (CF501) is a potent non-nucleotide *STING* agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research .

HY-164919

Calotatug ginistinag XMT-2056	Antibody-Drug Conjugates (ADCs) EGFR STING	Inflammation/Immunology Cancer
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate targeting HER2, with an effective payload connected via a linker (LP, HY-148067) to a *STING* agonist (STING agonist-20, HY-148068), and has potential immune activation and anticancer activity .

HY-177338

STING agonist-45	STING Cyclic GMP-AMP Synthase IFNAR TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
STING agonist-45 is a selective *STING* agonist (EC₅₀ = 0.28 μM). STING agonist-45 activates the innate immune response through the *cGAS-STING* pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust *STING* activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 ⁺ T cell infiltration in mouse models. STING agonist-45 is promising for the study of *STING*-related diseases .

HY-128481

SB24011	STING	Inflammation/Immunology Cancer
SB24011 is a *STING* modulator and a *TRIM29-STING* protein-protein interaction inhibitor. SB24011 blocks TRIM29-induced K48-linked specific ubiquitination by binding to *STING, thereby upregulating intracellular STING* protein levels. SB24011 enhances inflammatory cytokine expression and STING-mediated immune responses, and exhibits abscopal antitumor activity that promotes tumor regression and activates T cell infiltration. When combined with STING agonists or anti-PD1 antibodies, SB24011 synergistically enhances antitumor responses. SB24011 is suitable for research related to colon cancer and melanoma .

HY-150074

STING agonist-18	STING ADC Payload	Cancer
STING agonist-18 (compound 1a) is a *STING* agonist that can be used for synthesis of antibody-drug conjugates (ADCs), such Trastuzumab (HY-P9907) conjugate .

HY-137320

diABZI-C2-NH2	STING	Cancer
diABZI-C2-NH2, an active analogue containing a primary amine functionality, is a *STING* agonist .

HY-130115A

IACS-8803 disodium 1 Publications Verification	STING	Cancer
IACS-8803 disodium is a highly potent cyclic dinucleotide *STING* agonist. IACS-8803 disodium has a robust systemic antitumor efficacy .

HY-164278

diABZI-V/C-Mal	STING Cathepsin	Cancer
diABZI-V/C-Mal is a *STING* agonist (with a *STING* EC₅₀ of 314 nM in TH1 dual reporter cells) and a Cathepsin B substrate. diABZI-V/C-Mal activates *STING, thereby triggering the IRF3* signaling pathway. diABZI-V/C-Mal is cleaved by Cathepsin B to regenerate diABZI-NH₂ .

HY-139586

Ulevostinag MK-1454	STING	Cancer
Ulevostinag (MK-1454) is a potent cyclic dinucleotide agonist stimulator of interferon genes (STING). Ulevostinag (MK-1454) acts in the intra-tumoral route by targeting the stimulator of interferon genes (STING) protein. Ulevostinag (MK-1454) can be used for immuno-tumor cancer disease research .

HY-160406

SNX281	STING IFNAR Interleukin Related	Inflammation/Immunology Cancer
SNX281 is a selective *STING* agonist, with IC₅₀ values of 4.1, 4.5, 10.7, and 3.7 μM against human, mouse, rat, and monkey STING, respectively. SNX281 undergoes homodimerization at the STING binding site, triggering a conformational shift of STING from an inactive open state to an active closed state, thereby driving downstream *STING*-dependent signaling pathways. SNX281 induces type I interferons, IFN-β, TNF-α, IL-6, cytokine release, T cell responses, and long-lasting immune memory. SNX281 exhibits anti-tumor activity and is applicable to research related to colorectal cancer, melanoma, advanced solid tumors, lymphoma, and ovarian cancer .

HY-143896

STING agonist-7	STING	Cancer
STING agonist-7 is a non-nucleotide *STING* agonist. STING agonist-7 binds selectively to mouse STING but not human STING. STING agonist-7 penetrates cell membrane poorly .

HY-152959

STING agonist-26	STING	Infection Cancer
STING agonist-26 (CF508) is a non-nucleotide small-molecule *STING* agonist. STING agonist-23 activates STING, increases phosphorylation of *STING, TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .

HY-131994

STING agonist-16 1 Publications Verification	STING	Infection Cancer
STING agonist-16 (1a) is a specific stimulator of interferon genes (STING) agonist. STING agonist-16 (1a) can be used as a potential antiviral and antitumor tool .

HY-173425

STING-IN-15	STING IFNAR TNF Receptor Interleukin Related	Inflammation/Immunology
STING-IN-15 is an orally active *STING* inhibitor, with an IC₅₀ of 116 nM against *h-STING* and an IC₅₀ of 96.3 nM against *m-STING. STING-IN-15 inhibits the STING* signaling pathway in cells, reduces the secretion of IFN-β and IP-10, downregulates the expression of ISG15, ISG56 and TNF-α, and suppresses the phosphorylation of TBK1/IRF3. STING-IN-15 alleviates systemic and renal inflammation induced by STING agonists in mice, reduces tissue damage and the expression of interferon pathway genes, and inhibits spontaneous tissue inflammation in mice. STING-IN-15 can be used for the research of acute kidney injury and autoimmune/inflammatory diseases .

HY-103665A

STING agonist-3 trihydrochloride 5+ Cited Publications	STING	Cancer
STING agonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule *STING* agonist with a pEC₅₀ and pEC₅₀ of 7.5 and 9.5, respectively. STING agonist-3 trihydrochloride has durable anti-tumor effect and tremendous potential to improve treatment of cancer .

HY-141514

MSA-2 dimer 1 Publications Verification	STING	Inflammation/Immunology Cancer
MSA-2 dimer is a selective, orally active non-nucleotide *STING* agonist (K_d=145 μM) with long-term antitumor and immunogenic activity. MSA-2 dimer is bound to *STING* as a non-covalent dimer exhibiting higher permeability than cyclic dinucleotide .

HY-139179

STING agonist-14	STING	Infection Cancer
STING agonist-14 (compound 12b) is a potent *STING* agonist that is efficacious across species. STING agonist-14 could activate the pathway by directly binding human STING. STING agonist-14 can be used for the research of tumours or viral infections .

HY-175714

STING agonist-46	STING	Inflammation/Immunology Cancer
STING agonist-46 is an orally active STING agonist. STING agonist-46 activates the STING signaling pathway, promoting phosphorylation of TBK1 and IRF3, and secretion of IFN-β and IP-10. STING agonist-46 directly binds to STING and increases its thermal stability. STING agonist-46 demonstrates potent anti-tumor efficacy in B16F10, CT26, and 4T1 mouse models. STING agonist-46 can be used for cancer immunotherapy studies .

HY-152956

STING agonist-23	STING	Infection Cancer
STING agonist-23 (CF502) is a non-nucleotide small-molecule *STING* agonist. STING agonist-23 activates STING, increases phosphorylation of *STING, TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .

HY-148346

STING agonist-20-Ala-amide-PEG2-C2-NH2	Drug-Linker Conjugates for ADC STING	Cancer
STING agonist-20-Ala-amide-PEG2-C2-NH2 is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used for the research of cancer .

HY-176809

Parent CDN	STING	Cancer
Parent CDN is a cyclic dinucleotide and a *STING* agonist. Parent CDN exhibits anti-tumor activity .

HY-144329

STING agonist-11	STING	Inflammation/Immunology Cancer
STING agonist-11 (Compound 92) is a potent small molecule cyclic urea activator of *STING* with EC₅₀ of 18 nM. Activation of STING is a highly promising approach in immunotherapy .

HY-158048

UNC9036	PROTACs STING	Inflammation/Immunology
UNC9036 is a PROTAC-based *STING* degrader, with a DC₅₀ of 227 nM. UNC9036-mediated STING degradation is proteasome and VHL dependent (Structure Note: Red, STING agonist diABZI (HY-112921A); Blue, VHL ligand VH032 (HY-120217); Black, linker) .

HY-130115

IACS-8803	STING	Cancer
IACS-8803 is a highly potent cyclic dinucleotide *STING* agonist with robust systemic antitumor efficacy .

HY-150074A

STING agonist-18 diTFA	STING ADC Payload	Cancer
STING agonist-18 (compound 1a) diTFA is a *STING* agonist that can be used for synthesis of antibody-drug conjugates (ADCs), such Trastuzumab (HY-P9907) conjugate .

HY-162133

MSA-2-Pt	STING Apoptosis IKK IFNAR NF-κB	Cancer
MSA-2-Pt, platinum salt-modified MSA-2 (HY-136927), is a *STING* agonist. MSA-2-Pt inducing cell death by platinum and activating the STING pathway by MSA-2. MSA-2-Pt direct activates STING pathway, induces phosphorylation of TBK1, IRF3, and NF-κB p65. MSA-2-Pt enhances tumor infiltration of CD4 ⁺ and CD8 ⁺ T cells, and induces tumor cell death and apoptosis in mouse colon carcinoma and melanoma models .

HY-149781

STING agonist-34	STING	Cancer
STING agonist-34 (Compound 12L) is a potent *STING* agonist with an IC₅₀ value of 1.15 μM and an EC₅₀ of 0.38 μM in THP1 cells. STING agonist-34 could be used in cancer research .

HY-143321

STING agonist-13	STING	Cancer
STING agonist-13 is a stimulator of interferon genes (STING) agonist, for cancer immunity via STING-mediated immune activation. STING agonist-13 can stimulate *STING* downstream signaling and promoting type I interferon immune responses. STING agonist-13 significantly decreases tumor volume and shows immunological memory-derived cancer inhibition .

HY-152961

STING agonist-28	STING	Infection
STING agonist-28 (CF510) is a non-nucleotide small-molecule *STING* agonist. STING agonist-23 activates STING, increases phosphorylation of *STING, TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .

HY-178338

STING agonist-47	STING	Cancer
STING agonist-47 is a *STING* agonist with an EC₅₀ of 0.72 μM and a K_d of 176 nM. STING agonist-47 is a dimer of MSA-2 (HY-136927). STING agonist-47 can be used for the research of cancer, such as breast cancer .

HY-163668

MK-2118	STING	Cancer
MK-2118 is a GMP-synthesized *STING* agonist with the potential to inhibit advanced/metastatic solid tumors or lymphomas. .

HY-144168

STING agonist-8	STING	Inflammation/Immunology
STING agonist-8 is a potent *STING* agonist with an EC₅₀ of 27 nM in THP1-Dual KI-hSTING-R232 cells (WO2021239068A1, compound 5-AB) .

HY-168887

ZSA-51	STING	Cancer
ZSA-51 is a potent and orally active *STING* agonist. ZSA-51 shows anticancer activity. ZSA-51 remodeles immune microenvironment both in tumor and lymph node .

HY-152861

Dazostinag TAK-676 free base	STING	Cancer
Dazostinag (TAK-676 free base) is an agonist of stimulator of interferon genes (STING) protein with antineoplastic activity. Dazostinag can serve as a playload to synthesis antibody-drug conjugates (ADCs) .

HY-148346A

STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA	Drug-Linker Conjugates for ADC STING	Cancer
STING agonist-20-Ala-amide-PEG2-C2-NH2 (Compound 30b) TFA is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used for the research of cancer .

HY-178966

STING agonist-48	STING	Infection Inflammation/Immunology
STING agonist-48 is a potent STING agonist that exhibits STING-dependent activity in vitro (EC₅₀ = 4.02 μM). STING agonist-48 prefers to bind with the transmembrane domain (TMD) over the cytosolic cyclic dinucleotide (CDN) domain. STING agonist-48 shows adjuvant efficacy, enhancing IgG and Th1/Th2 cytokine responses in humanized STING mice. STING agonist-48 can be used for the study of inflammation-related diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-12326A

c-di-AMP disodium Maximum Cited Publications 16 Publications Verification Cyclic diadenylate disodium; Cyclic-di-AMP disodium	Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	STING Bacterial Endogenous Metabolite
c-di-AMP (Cyclic diadenylate) sodium is a *STING* agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP sodium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP sodium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .

HY-110382

Cyclic-di-GMP disodium 5+ Cited Publications c-di-GMP disodium; cyclic diguanylate disodium; 5GP-5GP disodium	Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	STING Endogenous Metabolite
Cyclic-di-GMP disodium is a *STING* agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research .

HY-12326

c-di-AMP Cyclic diadenylate; Cyclic-di-AMP	Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	STING Bacterial Endogenous Metabolite
c-di-AMP (Cyclic diadenylate) is a *STING* agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP (Cyclic diadenylate) is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP (Cyclic diadenylate) acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .

HY-107780

Cyclic-di-GMP c-di-GMP; cyclic diguanylate; 5GP-5GP	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	STING Endogenous Metabolite
Cyclic-di-GMP is a *STING* agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research .

HY-12326B

c-di-AMP diammonium Maximum Cited Publications 16 Publications Verification Cyclic diadenylate diammonium; Cyclic-di-AMP diammonium	Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	STING Bacterial Endogenous Metabolite
c-di-AMP diammonium is a *STING* agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP diammonium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP diammonium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .

HY-107780B

Cyclic-di-GMP diammonium 5+ Cited Publications c-di-GMP diammonium; cyclic diguanylate diammonium; 5GP-5GP diammonium	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	STING Endogenous Metabolite
Cyclic-di-GMP diammonium is a *STING* agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research .

HY-107780A

Cyclic-di-GMP sodium c-di-GMP sodium; cyclic diguanylate sodium; 5GP-5GP sodium	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	STING Endogenous Metabolite
Cyclic-di-GMP sodium is a *STING* agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research .

Cat. No.	Product Name	Chemical Structure

HY-110382S

Cyclic-di-GMP-13C20,15N10 disodium

¹³C20, ¹⁵N10-Cyclic di-GMP ( ¹³C20, ¹⁵N10-c-di-GMP) is ¹³C and ¹⁵N labeled Cyclic-di-GMP (disodium). Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research .

Cat. No.	Product Name		Classification

HY-162874

diABZI-V/C-DBCO		DBCO
diABZI-V/C-DBCO is a *STING* agonist with an EC₅₀ of 1.47 nM. diABZI-V/C-DBCO activates the *STING* pathway, induces the production of IFN-I, and stimulates the secretion of IFN-β. diABZI-V/C-DBCO serves as a substrate for cathepsin B, and releases active diABZI-amine via cathepsin B-mediated cleavage. In an orthotopic mouse model of breast cancer, diABZI-V/C-DBCO increases serum IFN-β levels and the frequency of granzyme B ⁺ CD8 ⁺ T cells. diABZI-V/C-DBCO is applicable to research related to triple-negative breast cancer .

HY-176126

STING agonist-42		Alkynes
STING agonist-42 (compound 8a) is a potent *STING* agonist. STING agonist-42 activates STING in THP1 and RAW 264.7 cells with EC₅₀s of 0.06 and 14.15 μM, respectively .

Cat. No.	Product Name		Classification

HY-171692

G3-YSD		CpG ODNs
G3-YSD is a cGAS agonist. G3-YSD directly interacts with cGAS to enhance its enzymatic activity, promote the conversion of ATP and GTP into cGAMP, and trigger *STING*-dependent IFN-α/β secretion. G3-YSD acts as a viral mimic to replace actual viral DNA . G3-YSD is applicable to research related to long COVID and type 1 human immunodeficiency virus infection .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks